Snigdha Jain1, Rohan Khera2, Saket Girotra3, David Badesch4, Zhen Wang5, Mohammad Hassan Murad5, Amy Blevins6, Gregory A Schmidt7, Siddharth Singh8, Alicia K Gerke7. 1. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: snigdha.jain@utsouthwestern.edu. 2. Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX. 3. Division of Cardiology, University of Iowa Carver College of Medicine, Iowa City, IA. 4. Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO. 5. Knowledge and Evaluation Research Unit and the Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN. 6. Hardin Library for the Health Sciences, University of Iowa Carver College of Medicine, Iowa City, IA. 7. Division of Pulmonary, Critical Care, and Occupational Medicine, University of Iowa Carver College of Medicine, Iowa City, IA. 8. Division of Biomedical Informatics, Department of Internal Medicine, University of California San Diego, La Jolla, CA.
Abstract
BACKGROUND: We conducted a systematic review and network meta-analysis to examine comparative efficacy and tolerability of pharmacologic interventions for pulmonary arterial hypertension (PAH). METHODS: MEDLINE, the Cochrane Register, EMBASE, CINAHL, and clinicaltrials.gov were searched (January 1, 1990 to March 3, 2016). Randomized controlled trials (RCTs) studying the approved pharmacologic agents endothelin receptor antagonists (ERA), phosphodiesterase inhibitors (PDE5i), the oral/inhaled (PO/INH) and IV/subcutaneous (SC) prostanoids, and riociguat and selexipag, alone or in combination, for pulmonary arterial hypertension (PAH) and reporting at least one efficacy outcome were selected. RESULTS: Thirty-one RCTs with 6,565 patients were selected. In network meta-analysis, when compared with a median placebo rate of 14.5%, clinical worsening was estimated at 2.8% with riociguat (risk ratio [RR], 0.19; 95% CI, 0.05-0.76); at 3.9% with ERA + PDE5i (RR, 0.27; 95% CI, 0.14-0.52), and at 5.7% with PDE5i (RR, 0.39; 95% CI, 0.24-0.62). For improvement in functional status, when compared with 16.2% in the placebo group, improvement in at least one New York Heart Association/World Health Organization (NYHA/WHO) functional class was estimated at 81.8% with IV/SC prostanoids (RR, 5.06; 95% CI, 2.3211.04), at 28.3% with ERA + PDE5i (RR, 1.75; 95% CI, 1.05-2.92), and at 25.2% with ERA (RR, 1.56; 95% CI, 1.22-2.00). Differences in mortality were not significant. Adverse events leading to discontinuation of therapy were highest with the PO/INH prostanoids (RR, 2.92; 95% CI, 1.68-5.06) and selexipag (RR, 2.06; 95% CI, 1.04-3.88) compared with placebo. CONCLUSIONS: Currently approved pharmacologic agents have varying effects on morbidity and functional status in patients with PAH. Future comparative effectiveness trials are warranted with a focus on a patient-centered approach to therapy. REGISTRATION: PROSPERO CRD42016036803.
BACKGROUND: We conducted a systematic review and network meta-analysis to examine comparative efficacy and tolerability of pharmacologic interventions for pulmonary arterial hypertension (PAH). METHODS: MEDLINE, the Cochrane Register, EMBASE, CINAHL, and clinicaltrials.gov were searched (January 1, 1990 to March 3, 2016). Randomized controlled trials (RCTs) studying the approved pharmacologic agents endothelin receptor antagonists (ERA), phosphodiesterase inhibitors (PDE5i), the oral/inhaled (PO/INH) and IV/subcutaneous (SC) prostanoids, and riociguat and selexipag, alone or in combination, for pulmonary arterial hypertension (PAH) and reporting at least one efficacy outcome were selected. RESULTS: Thirty-one RCTs with 6,565 patients were selected. In network meta-analysis, when compared with a median placebo rate of 14.5%, clinical worsening was estimated at 2.8% with riociguat (risk ratio [RR], 0.19; 95% CI, 0.05-0.76); at 3.9% with ERA + PDE5i (RR, 0.27; 95% CI, 0.14-0.52), and at 5.7% with PDE5i (RR, 0.39; 95% CI, 0.24-0.62). For improvement in functional status, when compared with 16.2% in the placebo group, improvement in at least one New York Heart Association/World Health Organization (NYHA/WHO) functional class was estimated at 81.8% with IV/SC prostanoids (RR, 5.06; 95% CI, 2.3211.04), at 28.3% with ERA + PDE5i (RR, 1.75; 95% CI, 1.05-2.92), and at 25.2% with ERA (RR, 1.56; 95% CI, 1.22-2.00). Differences in mortality were not significant. Adverse events leading to discontinuation of therapy were highest with the PO/INH prostanoids (RR, 2.92; 95% CI, 1.68-5.06) and selexipag (RR, 2.06; 95% CI, 1.04-3.88) compared with placebo. CONCLUSIONS: Currently approved pharmacologic agents have varying effects on morbidity and functional status in patients with PAH. Future comparative effectiveness trials are warranted with a focus on a patient-centered approach to therapy. REGISTRATION: PROSPERO CRD42016036803.
Authors: Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau Journal: N Engl J Med Date: 2005-11-17 Impact factor: 91.245
Authors: Gérald Simonneau; Adam Torbicki; Marius M Hoeper; Marion Delcroix; Kristóf Karlócai; Nazzareno Galiè; Bruno Degano; Diana Bonderman; Marcin Kurzyna; Michela Efficace; Ruben Giorgino; Irene M Lang Journal: Eur Respir J Date: 2012-02-23 Impact factor: 16.671
Authors: Vallerie McLaughlin; Richard N Channick; Hossein-Ardeschir Ghofrani; Jean-Christophe Lemarié; Robert Naeije; Milton Packer; Rogério Souza; Victor F Tapson; Jonathan Tolson; Hikmet Al Hiti; Gisela Meyer; Marius M Hoeper Journal: Eur Respir J Date: 2015-06-25 Impact factor: 16.671
Authors: Gerald Simonneau; Robyn J Barst; Nazzareno Galie; Robert Naeije; Stuart Rich; Robert C Bourge; Anne Keogh; Ronald Oudiz; Adaani Frost; Shelmer D Blackburn; James W Crow; Lewis J Rubin Journal: Am J Respir Crit Care Med Date: 2002-03-15 Impact factor: 21.405
Authors: N Galiè; Lj Rubin; Mm Hoeper; P Jansa; H Al-Hiti; Gmb Meyer; E Chiossi; A Kusic-Pajic; G Simonneau Journal: Lancet Date: 2008-06-21 Impact factor: 79.321
Authors: Vallerie V McLaughlin; Sean P Gaine; Robyn J Barst; Ronald J Oudiz; Robert C Bourge; Adaani Frost; Ivan M Robbins; Victor F Tapson; Michael D McGoon; David B Badesch; Jeff Sigman; Robert Roscigno; Shelmer D Blackburn; Carl Arneson; Lewis J Rubin; Stuart Rich Journal: J Cardiovasc Pharmacol Date: 2003-02 Impact factor: 3.105
Authors: Horst Olschewski; Gerald Simonneau; Nazzareno Galiè; Timothy Higenbottam; Robert Naeije; Lewis J Rubin; Sylvia Nikkho; Rudolf Speich; Marius M Hoeper; Jürgen Behr; Jörg Winkler; Olivier Sitbon; Wladimir Popov; H Ardeschir Ghofrani; Alessandra Manes; David G Kiely; Ralph Ewert; Andreas Meyer; Paul A Corris; Marion Delcroix; Miguel Gomez-Sanchez; Harald Siedentop; Werner Seeger Journal: N Engl J Med Date: 2002-08-01 Impact factor: 91.245
Authors: Rohan Khera; Ambarish Pandey; Apoorva K Chandar; Mohammad H Murad; Larry J Prokop; Ian J Neeland; Jarett D Berry; Michael Camilleri; Siddharth Singh Journal: Gastroenterology Date: 2018-01-03 Impact factor: 22.682
Authors: Lia N Pizzicato; Vijay R Nadipelli; Samuel Governor; Jianbin Mao; Stephan Lanes; John Butler; Rebecca S Pepe; Hemant Phatak; Karim El-Kersh Journal: Pulm Circ Date: 2022-06-08 Impact factor: 2.886
Authors: Karin P Potoka; Katherine C Wood; Jeffrey J Baust; Marta Bueno; Scott A Hahn; Rebecca R Vanderpool; Tim Bachman; Grace M Mallampalli; David O Osei-Hwedieh; Valerie Schrott; Bin Sun; Grant C Bullock; Eva-Maria Becker-Pelster; Matthias Wittwer; Jan Stampfuss; Ilka Mathar; Johannes-Peter Stasch; Hubert Truebel; Peter Sandner; Ana L Mora; Adam C Straub; Mark T Gladwin Journal: Am J Respir Cell Mol Biol Date: 2018-05 Impact factor: 6.914
Authors: Robert I Liem; Sophie Lanzkron; Thomas D Coates; Laura DeCastro; Ankit A Desai; Kenneth I Ataga; Robyn T Cohen; Johnson Haynes; Ifeyinwa Osunkwo; Jeffrey D Lebensburger; James P Lash; Theodore Wun; Madeleine Verhovsek; Elodie Ontala; Rae Blaylark; Fares Alahdab; Abdulrahman Katabi; Reem A Mustafa Journal: Blood Adv Date: 2019-12-10
Authors: Charles D Burger; Mohamedanwar Ghandour; Divya Padmanabhan Menon; Haytham Helmi; Raymond L Benza Journal: Clinicoecon Outcomes Res Date: 2017-11-24